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Structural characterization of clusterin-chaperone client protein complexes 
Abstract 
Clusterin (CLU) is a potent extracellular chaperone that inhibits protein aggregation and precipitation 
otherwise caused by physical or chemical stresses (e.g. heat, reduction). This action involves CLU 
forming soluble high molecular weight (HMW) complexes with the client protein. Other than their 
unquantified large size, the physical characteristics of these complexes were previously unknown. In this 
study, HMW CLU-citrate synthase (CS), HMW CLU-fibrinogen (FGN), and HMW CLU-glutathione 
S-transferase (GST) complexes were generated in vitro, and their structures studied using size exclusion 
chromatography (SEC), ELISA, SDS-PAGE, dynamic light scattering (DLS), bisANS fluorescence, and 
circular dichroism spectrophotometry (CD). Densitometry of Coomassie Blue-stained SDS-PAGE gels 
indicated that all three HMW CLU-client protein complexes had an approximate mass ratio of 1:2 
(CLU:client protein). SEC indicated that all three clients formed complexes with CLU ≥ 4 × 107 Da; 
however, DLS estimated HMW CLU-FGN to have a diameter of 108.57 ± 18.09 nm, while HMW CLU-CS and 
HMW CLU-GST were smaller with estimated diameters of 51.06 ± 6.87 nm and 52.61 ± 7.71 nm, 
respectively. Measurements of bisANS fluorescence suggest that the chaperone action of CLU involves 
preventing the exposure to aqueous solvent of hydrophobic regions that are normally exposed by the 
client protein during heat-induced unfolding. CD analysis indicated that, depending on the individual client 
protein, CLU may interact with a variety of intermediates on protein unfolding pathways with different 
amounts of native secondary structure. In vivo, soluble complexes like those studied here are likely to 
serve as vehicles to dispose of otherwise dangerous aggregation-prone misfolded extracellular proteins. 
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Clusterin (CLU) is a potent extracellular 
chaperone that inhibits protein aggregation 
and precipitation otherwise caused by physical 
or chemical stresses (e.g. heat, reduction). This 
action involves CLU forming soluble high 
molecular weight (HMW) complexes with the 
client protein. Other than their unquantified 
large size, the physical characteristics of these 
complexes were previously unknown. In this 
study, HMW CLU-citrate synthase (CS), 
HMW CLU-fibrinogen (FGN) and  
HMW CLU-glutathione-S-transferase (GST) 
complexes were generated in vitro and their 
structures studied using size exclusion 
chromatography (SEC), ELISA, SDS-PAGE, 
dynamic light scattering (DLS), bisANS 
fluorescence, and circular dichroism 
spectrophotometry (CD). Densitometry of 
Coomassie-stained SDS-PAGE gels indicated 
that all three HMW CLU-client protein 
complexes had an approximate mass ratio of 
1:2 (CLU:client protein). SEC indicated that 
all three clients formed complexes with CLU 
 4 x 10
7
 Da, however, DLS estimated  
HMW CLU-FGN to have a diameter of  
108.57 ± 18.09, while HMW CLU-CS and 
HMW CLU-GST were smaller with estimated 
diameters of 51.06 ± 6.87 nm and  
52.61 ± 7.71 nm, respectively. Measurements 
of bisANS fluorescence suggest that the 
chaperone action of CLU involves preventing 
the exposure to aqueous solvent of 
hydrophobic regions that are normally 
exposed by the client protein during  
heat-induced unfolding. CD analysis indicated 
that, depending on the individual client 
protein, CLU may interact with a variety of 
intermediates on protein unfolding pathways 
with different amounts of native secondary 
structure. In vivo, soluble complexes like those 
studied here are likely to serve as vehicles to 
dispose of otherwise dangerous aggregation-
prone misfolded extracellular proteins. 
 
Controlled unfolding is important in 
many biological processes including protein 
translocation, degradation by proteases and 
regulation of enzyme activity. Uncontrolled 
unfolding and the consequent accumulation of 
insoluble protein aggregates is implicated in the 
pathology of many diseases including 
Alzheimer’s disease and type II diabetes and is 
promoted by various stresses such as oxidative 
stress (1), shear stress (2) and thermal stress (3). 
Cells have extensive quality control mechanisms 
to ensure that intracellular proteins are maintained 
predominantly in their native conformations. 
Molecular chaperones are known to play a central 
role in these systems by targeting unfolded 
proteins for refolding or degradation (4-7). 
However, little is known about the existence of 
corresponding systems for protein folding quality 
control in the extracellular environment (8).  
A large number of alternative functions 
have been proposed for clusterin (CLU), 
nevertheless, the potent chaperone activity of this 
protein (9-13) and its constitutive presence in 
many biological fluids suggests that it is likely to 
be important in extracellular protein folding 
quality control. Recently haptoglobin (14) and 2-
macroglobulin (15,16) have also been identified 
as extracellular chaperones. All three proteins 
exhibit small heat shock protein (sHsp)-like 
activity, preferentially binding to stressed client 
proteins to prevent their precipitation in an ATP-
independent manner (9,11,14,16). When acting 
alone, extracellular chaperones lack refolding 
activity, however it has been shown that CLU can 
hold partially unfolded proteins in a state 
competent for refolding by Hsc70 (11). 
CLU is found associated with 
extracellular protein deposits in numerous 
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diseases including drusen in age-related macular 
degeneration (17), renal immunoglobulin deposits 
in kidney disease (18), Lewy bodies in 
Parkinson’s disease (19), prion deposits in 
Creutzfeldt-Jakob disease (20) and amyloid 
plaques in Alzheimer’s disease (21). Knock-out 
studies have shown that CLU-deficient mice 
accumulate insoluble protein deposits in the 
kidneys and develop progressive glomerulopathy 
(22). These findings suggest a role for CLU in the 
clearance of extracellular misfolded proteins, 
however, the mechanism by which this may occur 
has yet to be determined.  
Currently, little is known about the 
physical characteristics of the soluble complexes 
formed during the interaction of CLU with 
chaperone client proteins (9-12). This is the first 
study to investigate the physical properties of 
CLU-client protein complexes. The present study 
provides new insights into the properties of 
complexes formed in vitro between CLU and 
citrate synthase (CS), fibrinogen (FGN) and 




Materials - 4,4’-Bis(1-anilino-8-naphthalene 
sulfonate; bisANS), bovine serum albumin 
(BSA), CS, and FGN were all obtained from 
Sigma-Aldrich. All buffer salts and H2O2 were 
obtained from Ajax Chemical Co. Human blood 
was obtained as a kind gift from Wollongong 
Hospital (Wollongong, NSW, Australia) and 
processed to yield plasma, which was stored 
frozen at -20ºC until used. CLU was purified  
from human plasma by immunoaffinity 
chromatography as previously described (23). 
GST was expressed in E. coli using the vector 
pGEX-2T (without an insert; Invitrogen) as 
previously described (24) and purified using a 
Glutathione SepharoseTM High Performance 
column according to the manufacturer’s 
directions (GE Healthcare). 
Precipitation Assays - CS (6.0 μM), FGN 
(6.0 μM) or GST (20 μM) were incubated at 
41ºC, 45ºC or 60ºC, respectively, in phosphate 
buffered saline (PBS; 137 mM NaCl, 2.7 mM 
KCl, 1.5 mM KH2PO4, and 8 mM Na2HPO4, pH 
7.4) containing 0.1% (w/v) NaN3 (PBS/Az) in the 
presence or absence of CLU (6.6 μM, 6.5 μM and 
3.2 μM, respectively) or the control protein, BSA 
(at the same respective molar concentrations). The 
solutions were added in triplicate 100 μl aliquots 
to a 384 well plate (Greiner Bio-one). Protein 
precipitation was monitored by measuring the 
absorbance at 360 nm (A360 nm; an indication of 
turbidity) with a FLUOstar Optima incubator 
microplate reader (BMG Labtechnologies). 
Preparation of Preheated Protein 
Controls - Preheated control proteins were 
prepared by incubating client proteins or CLU 
(alone) at the same temperature and for the same 
duration used to form the HMW complexes. 
Preheated controls were filtered (0.45 μm) and the 
clarified solutions assayed for residual protein 
content using the bicinchoninic micro-protein 
assay (25), or the respective extinction 
coefficients at 280 nm. 
Size Exclusion Chromatography (SEC) - 
SEC was carried out using a SuperoseTM 6 10/300 
column (GE Healthcare) at the recommended 
flow rate of 0.5 ml/min and the absorbance at  
280 nm continuously monitored using an ÄKTA 
FPLC system (GE Healthcare). Mass standards 
were from a commercial high molecular weight 
calibration kit (GE Healthcare). All buffers and 
samples were filtered (0.45 μm) before use. SEC 
purified HMW complexes were collected from 
fractions between 7-8 ml in the peak 
corresponding to the size exclusion limit of  
 4 x 107 Da. The integrity of the complexes was 
checked periodically by reanalysis using the same 
column.  
Sandwich ELISA - The wells of an 
ELISA plate (Greiner Bio-one) were coated with 
purified G7 anti-CLU antibody (23), then blocked 
with 1% (w/v) BSA in PBS (BSA/PBS). Mixtures 
of CLU and client protein were heated as 
described in Precipitation Assays and fractionated 
by SEC (as described above). After washing with 
PBS, proteins eluting at the exclusion limit  
(  4 x 107 Da), preheated CLU or client proteins, 
or a mixtures of CLU and individual client 
proteins were incubated in the wells of the ELISA 
plate (diluted to 50 μg/ml in BSA/PBS). Then a 
primary antibody (or antiserum) reactive with the 
client protein, diluted in BSA/PBS, was added 
following the manufacturer’s instructions. Finally 
an appropriate horseradish peroxidase conjugated 
secondary antibody diluted in BSA/PBS was 
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added following the manufacturer’s instructions. 
All incubations were carried out for 1 h at 37ºC 
with shaking and washing was performed with 
PBS. After a final wash, ortho-phenylenediamine 
at 2.5 mg/ml in 50 mM citric acid, 100 mM 
Na2HPO4, pH 5, was added. The absorbance at 
490 nm (A490 nm) was measured using a 
SpectraMax Plus384 microplate reader (Molecular 
Devices). Non-specific binding was assessed 
using a species–matched polyclonal antibody or 
serum of irrelevant specificity and the appropriate 
secondary antibody. Primary antibodies used 
were sheep polyclonal anti-CS (IgG fraction, 
Abcam), goat anti-FGN antiserum and rabbit 
polyclonal anti-GST (IgG fraction, Chemicon). 
The respective controls were polyclonal anti-
Apolipoprotein A1 (IgG fraction, Abcam), 
normal goat serum (Sigma-Aldrich) and purified 
normal rabbit IgG fraction (Sigma-Aldrich). 
Dynamic Light Scattering (DLS) - 
Solutions of SEC purified HMW CLU-CS, HMW 
CLU-FGN and HMW CLU-GST complexes, 
CLU, FGN, CS or GST (controls were preheated 
or untreated), or mixtures of these proteins, were 
made between 0.1-1.0 mg/ml in PBS and filtered 
(0.45 μm). Triplicate samples were examined in 
low volume plastic cuvettes using a Zetasizer 
Nano ZS (Malvern). Particle diameters were 
recorded as a frequency distribution curve and the 
average diameter and range (average peak and 
width of 9 normally distributed curves) reported.  
Densitometry - Several mg of CS, FGN, 
GST or CLU were extensively dialyzed against 
distilled water and then freeze-dried. The 
recovered protein was weighed using a XS205 
Dual Range analytical balance (Mettler Toledo). 
The proteins were redissolved in an appropriate 
volume of filtered (0.45 μm) PBS and the 
absorbance at 280 nm of several aliquots 
measured using a SpectraMax Plus 384 
microplate reader (Molecular Devices). The 
average absorbance at 280 nm and the known 
protein concentration were used to calculate the 
extinction coefficient using Beer’s law. These 
proteins, as well as SEC purified HMW CLU-CS, 
HMW CLU-FGN and HMW CLU-GST 
complexes were reduced by boiling in SDS-
PAGE loading buffer containing 100 mM 
dithiothreitol and 1 % (v/v) -mercaptoethanol 
and separated on a 12 % SDS gel. Six sample 
wells containing unknown amounts of reduced 
HMW CLU-CS, HMW CLU-FGN or HMW 
CLU-GST complexes and triplicate wells 
containing 0.5-6 μg of reduced CS, FGN, GST or 
CLU were also loaded onto the gel. Following 
Coomassie blue staining and destaining, the major 
bands corresponding to reduced CS, FGN, GST 
and CLU were analyzed using a GS 800 
calibrated densitometer (Bio-Rad) and Quantity 
One software (Bio-Rad). The average optical 
density/mm2 of the major bands was used to 
construct a standard curve for each protein. Using 
these standard curves, the relative amounts of 
CLU and FGN, CS or GST present in the SEC 
purified HMW complexes were calculated. 
4,4 -Dianilino-1,1 -binaphthyl-5,5 -
disulfonic acid (bisANS) - For bisANS analyses, 
CLU client proteins (0.5 mg/ml CS,  
2 mg/ml FGN, or 0.5 mg/ml GST), or mixtures of 
client proteins (at the same concentrations) and 
CLU (at 0.4 mg/ml for experiments using CS or 
FGN, or at 0.2 mg/ml for experiments using GST) 
were incubated under the same conditions used to 
form HMW CLU-client protein complexes (see 
above). At specified time points, samples were 
taken from the solutions and snap frozen in liquid 
nitrogen. Following completion of the time 
courses, all samples were thawed and 
immediately diluted in PBS containing bisANS to 
give final concentrations of 50 μg/ml client 
protein and 10 μM bisANS. Samples containing 
CLU alone were diluted to give equivalent 
concentrations to that present in the (CLU + client 
protein) samples (i.e. 15 μg/ml or 30 μg/ml). 
Fluorescence was measured on a FLUOstar 
Optima fluorescence plate reader using excitation 
and emission windows of 360 +/-10 and  
490 +/-10 nm, respectively.  
Circular Dichroism (CD) - For CD 
analyses, samples were analyzed as previously 
described (26); all samples were in 10 mM 
Na2HPO4, pH 7.4. Individual proteins were 
analyzed before and after heating (the latter were 
residual soluble protein) at the following 
concentrations: CLU at 164 μg/ml, CS at 119 
μg/ml, FGN at 164 μg/ml, and GST at 110 μg/ml. 
In separate experiments, spectra were acquired for 
HMW complexes of CLU-CS (119 μg/ml), CLU-
FGN (164 μg/ml), CLU-GST (110 μg/ml), and 
solutions of CLU or the individual client proteins 
at concentrations corresponding to those present 
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in the complexes analyzed (calculated on the basis 
of the mass ratios of CLU:client protein in the 
complexes). Estimates of secondary structure 
were obtained using the program CDSSTR (27).  
 Thioflavin T Analyses - For thioflavin T 
fluorescence assays, all samples were prepared at 
50 μg/ml in PBS and contained 62.5 μM 
thioflavin T; fluorescence was measured using a 
FLUOstar Optima microplate reader (BMG 
Labtechnologies), with an excitation wavelength 
of 440 nm and an emission wavelength of 490 nm 
(slit-width 10 nm). Lysozyme amyloid was 




In Vitro Formation of CLU-Client 
Protein Complexes. When incubated alone at 
41ºC, 6 μM CS showed a progressive increase in 
turbidity (increasing A360 nm; Fig. 1A) from 0 to 
about 500 min. No further increase in turbidity 
was observed after approximately 500 min. Under 
the same conditions, when CLU was present with 
CS at a near equimolar concentration, no 
increases in turbidity were detected, indicating 
that CS was stabilized in solution. At the same 
concentration BSA had little effect on the 
precipitation of CS. Incubation of FGN alone at 
45°C resulted in progressive precipitation of the 
protein after an initial lag phase of approximately 
200 min - no further increases in turbidity were 
measured after 800 min (Fig. 1B). Under the 
same conditions, co-incubation of 6.5 μM CLU 
with 6.0 μM FGN completely abolished any 
increase in turbidity; in contrast, 6.5 mM BSA 
had little effect on the precipitation of FGN. 
Incubation of 20 μM GST at 60°C resulted in 
rapid precipitation of the protein after a lag phase 
of approximately 25 min (Fig. 1C). After 40 min 
the protein solution reached maximum turbidity 
and prolonged heating had no further effect. Co-
incubation of 20 μM GST with 3.2 μM CLU 
almost completely inhibited the precipitation of 
GST under the same conditions. This was in 
contrast to co-incubation with 3.2 μM BSA, 
where the protein solution exhibited a similar 
precipitation profile to that observed when GST 
was incubated alone. However, the maximum 
turbidity was marginally less in the presence of 
BSA. Both CLU and BSA were stable when 
incubated alone at 41-60ºC (data only shown for 
60ºC; Fig. 1C). As first reported by Humphreys et 
al. (1999) the effect of CLU on protein 
precipitation was dose-dependent for all client 
proteins (data not shown). 
Production of Preheated Protein 
Controls. To produce preheated protein controls, 
solutions of individual proteins were heated as 
described above and insoluble protein removed by 
filtration through a 0.45 μm filter. There was no 
difference in the SEC profiles of unheated  
CS, FGN, GST or CLU and the residual 
corresponding proteins remaining in solution after 
the respective heat treatments (Fig. 2). Also, when 
the residual, soluble heat-treated proteins were 
mixed, very little interaction was detected by SEC 
between CLU and CS (Fig. 2A), CLU and FGN 
(Fig. 2B), or CLU and GST (Fig. 2C).  
Detection of HMW complexes by SEC. 
SEC fractionation of the heat stressed mixtures of 
CLU and CS (41ºC), CLU and FGN (45ºC) or 
CLU and GST (60ºC) showed that they contained 
HMW species eluting at the exclusion limit of the 
column (  4 x 107 Da) that were absent from the 
same mixtures left unheated, and from solutions 
of the individual proteins (Fig. 2). Compared to 
FGN and GST, co-incubation of CS with CLU at 
41ºC produced proportionally less HMW species, 
however, it was evident that complexes 
comparable in mass to those formed at higher 
temperatures by CLU and FGN or GST were also 
formed by CLU and CS. The exclusion limit peak 
was collected in each case and represented 
putative HMW CLU-client protein complexes. 
The identity of these complexes was confirmed by 
sandwich ELISA (see below). These complexes 
were stored in PBS/Az at 4ºC and their integrity 
checked at intervals by SEC; under these 
conditions they remained stable for months.  
 Sandwich ELISA to Confirm the Identity 
of CLU-Client Protein Complexes. Sandwich 
ELISA designed to capture CLU and 
subsequently detect CS, FGN or GST was used to 
confirm the identity of the putative complexes 
purified by SEC. Relative to the samples 
containing the HMW complexes, little 
absorbance was obtained for control samples 
(Fig. 3).  
 Estimates of Stoichiometry Within 
Complexes. To estimate the stoichiometry of 
individual proteins within the HMW complexes, 
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SEC purified complexes were separated by  
SDS-PAGE under reducing conditions, the gels 
stained with Coomassie blue, and the intensity  
of individual protein bands quantified by 
densitometry. After standard curves were 
generated for each protein, the approximate mass 
ratios and molar ratios for each complex were 
calculated. The mass ratio of CLU to client 
protein was similar for CS, FGN and GST 
complexes (about 1:2 in each case). However, the 
molar ratios were very different - HMW CLU-CS 
complexes contained approximately the same 
number of molecules of CS and CLU, HMW 
CLU-FGN complexes contained about  
3 molecules of CLU for every FGN molecule, 
while CLU-GST complexes contained  
5 molecules of GST for each molecule of CLU 
(Table 1). These estimated CLU:client protein 
ratios were employed when selecting controls for 
structural studies of the HMW complexes. 
Size Estimation by Dynamic Light 
Scattering. The results of DLS were consistent 
between 0.1 and 1 mg/ml; representative results 
obtained at 0.5 mg/ml are shown (Fig. 4). In 
contrast to SEC, DLS was unable to resolve the 
differently sized oligomers of CLU in solution; 
DLS analysis of CLU samples indicated a 
normally distributed particle size. There was no 
apparent difference in size between native and 
preheated control proteins. The limitations of 
DLS in determining the respective diameters of 
particles of similar size, resulted in a peak 
corresponding to an intermediate size (compared 
to the individual proteins) when mixtures of 
residual preheated CLU and CS FGN or GST 
were analyzed. DLS indicated that SEC purified 
HMW CLU-CS and HMW CLU-GST were 
approximately six times larger than either of their 
respective components, while HMW CLU-FGN 
was more than 8 times larger than CLU or FGN 
(Fig. 4). 
 BisANS and Thioflavin T Fluorescence 
Assays. The bisANS fluorescence of individual 
soluble preheated client proteins showed time 
dependent changes. For CS, there was a gradual 
increase in fluorescence peaking at 6 h, before 
declining at 8 h (Fig. 5A). FGN showed transient 
peak fluorescence at 1-2 h before returning to the 
level of the unheated control (Fig. 5B). For GST, 
the fluorescence was increased over the period 1-
3 h before declining at 4 h (Fig. 5C). In contrast, 
the bisANS fluorescence of solutions of CLU 
heated alone only displayed a small increase at  
1 h and 6 h after heating at 45 ºC (Fig. 5); CLU 
did not precipitate under any of these conditions 
(data not shown). In all cases, at times when 
preheated soluble client protein showed increased 
bisANS fluorescence, the corresponding 
fluorescence of the respective preheated mixtures 
of CLU and client protein showed a lesser change. 
This suggests that the interaction between CLU 
and partially unfolded client proteins in theses 
mixed solutions reduces the extent to which 
hydrophobic regions on the client proteins are 
exposed to solvent. 
Thioflavin T analyses were carried out to 
determine if SEC purified complexes possessed 
any amyloid-like characteristics (i.e. contained 
beta-sheet rich structures). SEC purified HMW 
CLU-FGN and CLU-GST complexes and the 
relevant native and preheated protein controls all 
produced less than 8% of the fluorescence arising 
from a sample of lysozyme amyloid present at the 
same mass concentration (data not shown). 
Circular Dichroism Spectrophotometry. 
The CD spectrum for unheated CLU indicated 
high -helical content with minima at ~208 nm 
and ~222 nm. The molar elipticity at these 
wavelengths slightly increased when CLU was 
preheated at 43ºC or 60ºC. Under these 
conditions, CDSSTR analysis predicted a large 
decrease in -helical content, a similarly large 
increase in predicted -sheet content and smaller 
increases in the predicted contents of -turn and 
unordered structure (Fig. 6A; Table 2). However, 
heating at 41ºC only produced small increases in 
the predicted content of -sheet and -turn 
structure (Fig. 6A; Table 2). Preheated CS had a 
CD spectrum superimposable on that of unheated 
CS (Fig. 6B). In contrast, following heating at 
45ºC, FGN showed a change in minima from 
~222 nm to ~200 nm, consistent with the 
following predicted changes: a small decrease in 
-helical content, a moderate decrease in -sheet, 
and small increases in -turn and unordered 
structure content (Fig. 6C; Table 2). After heating 
at 60ºC, GST also showed a change in minima 
from that typical of high -helical to a more 
disordered structure. CDSSTR predicted a 
substantial decrease in -helical content and much 
smaller increases in -sheet, -turn and unordered 
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structure content (Fig. 6D; Table 2). Comparing 
the CD spectra of SEC purified HMW CLU-CS 
complexes with those of mixtures of the native or 
soluble preheated client proteins suggested that 
secondary structure was significantly altered in 
HMW CLU-CS complexes (Fig. 6E). This was 
largely attributed to a predicted loss of more than 
half the native -helical content, compared to the 
unheated proteins (Table 2). Analysis of the 
spectrum of a mixture of soluble preheated CS 
and preheated CLU predicted that, relative to the 
CLU-CS complex, the proteins had a smaller 
decrease in -helical content and an increase in 
unordered structure. In contrast the CD spectrum 
for HMW CLU-FGN complexes was virtually 
superimposable on that of a mixture of native 
CLU and FGN (Fig. 6F; Table 2). However, a 
corresponding mixture of preheated CLU and 
preheated FGN had a very different CD spectrum, 
consistent with the loss of predicted structure for 
the individual proteins following heating. It was 
evident that the formation of HMW CLU-GST 
complexes was accompanied by changes  
in secondary structure (Fig. 6G). For these 
complexes, relative to a mixture of the native 
proteins, there were predicted significant losses of 
-helical content, a large increase in -sheet 
content, and small increases in -turn and 
unordered structure (Table 2). The CD spectrum 
and predicted losses of secondary structure were 
similar for HMW CLU-GST complexes and a 




 Although CS (normally 
intracellular), FGN (normally extracellular and 
highly glycosylated) and GST (recombinant) are 
very different proteins with a large discrepancy in 
mass (approximately 52, 340 and 23 kDa, 
respectively), and the complexes with CLU were 
formed using very different conditions (41ºC, 
45ºC or 60ºC, respectively), in all cases the 
estimated mass stoichiometry of CLU:client 
protein in the complexes was about 1:2 (Table 1). 
In other words, in each case, CLU formed soluble 
complexes in which it "carried" about twice its 
own mass in the form of client protein. The molar 
ratio of CLU:client protein was quite different for 
each type of complex (Table 1), suggesting that 
the relative total masses of CLU and client protein 
limit the structure of the complexes and not their 
respective molar ratios. However, investigation of 
a larger number of client proteins is needed to 
confirm this interpretation. SEC indicated that all 
types of client protein generated complexes  
 4 x 107 Da in vitro (Fig. 2). DLS measurements 
suggested that CLU-FGN complexes had a 
diameter approximately twice that of CLU-CS or 
CLU-GST complexes (approximately 100 versus 
50 nm; Fig. 4). At this scale, the soluble  
CLU-client protein complexes are very large 
indeed, being of a similar size to virus particles.  
Measurements of bisANS fluorescence 
indicated that heat treatment induced CS, FGN 
and GST to expose more hydrophobicity to 
solution (Fig. 5). However, at least for FGN and 
GST, after 4 h of heating the level of solvent-
exposed hydrophobicity had returned to that of 
the respective zero time samples (or less). This 
may be because at these later time points a 
significant fraction of the client protein had 
precipitated from solution and was no longer 
available to bind bisANS. The bisANS 
fluorescence of solutions of CLU alone heated at 
41ºC and 60ºC did not show any significant 
changes over the time courses measured (Fig. 5A 
& Fig. 5C). Furthermore, although there were 
some statistically significant differences 
measured, there was no large or consistent change 
in the bisANS fluorescence of CLU heated alone 
at 45ºC (Fig. 5B). A clear trend in all three cases 
is that the bisANS fluorescence of mixtures of 
CLU and client protein increased significantly 
less during heating than was seen for 
corresponding heated solutions of client protein 
alone (Fig. 5). Thus, the data shown strongly 
suggests that co-incubation with CLU reduced the 
extent to which client proteins exposed 
hydrophobicity to solution when heated. 
Therefore it appears likely that the molecular 
interactions involved in the formation of  
CLU-client protein complexes either shield 
hydrophobic regions on the client protein from 
exposure to solution and/or prevent structural 
changes that would otherwise occur to result in 
their exposure. Previous work has implicated the 
binding of CLU to regions of exposed 
hydrophobicity on client proteins as an integral 
part of its chaperone action (10).  
Remarkably, the CD spectra acquired 
indicated that HMW CLU-FGN complexes had a 
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predicted overall content of the various secondary 
structures indistinguishable from that of a mixture 
of native CLU and FGN at the same 
concentrations (Fig. 6F). The most likely 
interpretation of this result is that, under the 
conditions tested, the interaction between CLU 
and FGN resulted in a mutual stabilization of 
secondary structures. Interestingly, the situation 
was quite different when examining complexes 
formed between CLU and CS or GST. In these 
cases, the predicted loss of overall -helical 
structure in the complexes was the same or 
greater than that in the corresponding mixture of 
preheated CLU and soluble preheated client 
protein. However, the complexes had more 
predicted -sheet content and slightly less -turn 
and unordered structure than the corresponding 
mixture of previously heated proteins (Table 2). 
The differences observed may be due to the 
differing inherent stabilities of the client proteins 
and the nature of secondary structure of unfolded 
intermediate states they display. 
Especially under conditions of 
pathological stress, but also under normal 
physiological conditions, it is likely that in 
extracellular fluids CLU-client protein complexes 
will form as a mechanism to combat the 
development of insoluble protein aggregates 
which can give rise to a variety of disease 
conditions (8). Results presented here suggest that 
CLU may interact with unfolding proteins at 
different points along their respective unfolding 
pathways. Depending on the point at which this 
interaction occurs, CLU may maintain the native 
secondary structures of the client protein or 
stabilize the client in some other non-native but 
stable conformation. The interactions between 
CLU and the client protein are likely to involve 
CLU shielding regions of exposed 
hydrophobicity.  
Physiological factors such as 
macromolecular crowding and shear stress are 
likely to favor protein aggregation in vivo 
compared to low concentrations of purified 
proteins in simple buffers (2,29,30). Thus, like 
many other studies of chaperone action, we used 
elevated temperature to induce client proteins to 
unfold and interact with CLU in vitro. CLU is 
very heat-stable and heating up to at least 60ºC 
does not inhibit its chaperone action (9,12). 
Mammals experience sporadic increases in body 
temperature as a result of physical activity (31), 
environmental exposure (32) and infection (33); 
fevers of up to 42ºC have been reported (34). 
Thus, the mild heat stress (41ºC) used to induce 
the precipitation of CS is encountered 
physiologically. Despite the differing conditions 
required for their formation in vitro, all three 
types of complexes shared the following features: 
a CLU:client protein mass ratio of 1:2, very large 
size (  4 x 107 Da by SEC, and diameters of  
50-100 nm by DLS), and reduced exposed 
hydrophobicity on the client protein (compared to 
client protein heated alone). It appears reasonable 
to expect that these shared characteristics give us 
important insights into the biophysical properties 
of CLU-client protein complexes in general and 
add to our mechanistic understanding of the 
chaperone action of CLU. 
In unpublished work, we have shown that 
when human plasma is "stressed" by gentle 
rotation for 10 days at 37ºC, the plasma contains 
CLU-FGN complexes (detected by sandwich 
ELISA), and when fractionated by SEC both CLU 
and FGN are present in fractions corresponding to 
molecules  4 x 107 Da (manuscript in 
preparation). Thus, it appears likely that CLU-
client protein complexes generated in situ in 
plasma are likely to include species of the sizes 
reported here for complexes formed in vitro from 
purified proteins. It is not possible to purify intact 
CLU-client protein complexes from plasma by 
immunoaffinity chromatography because the 
harsh elution conditions (2M GdHCl) will at least 
partly disrupt intermolecular interactions. 
Inappropriately aggregating proteins can 
be cytotoxic and also give rise to large 
pathological deposits which can interfere with 
organ/tissue function (35-39). In vivo, the 
sequestration of misfolded proteins into large, 
soluble complexes with extracellular chaperones 
like CLU is likely to be the first step in preventing 
them from forming toxic or otherwise 
pathological aggregates. On the basis of evidence 
reviewed elsewhere, we have proposed that these 
soluble complexes are probably rapidly cleared 
from the body by receptor-mediated endocytosis 
and subsequent lysosomal degradation (8,40). It 
will be important to demonstrate that this process 
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sodium dodecyl sulfate polyacrylamide gel electrophoresis; BSA, bovine serum albumin; ELISA, enzyme-
linked immunosorbent assay; PBS, phosphate buffered saline; bisANS, 4,4 -dianilino-1,1 -binaphthyl-5,5 -

















 Table 1. Approximate mass and molar ratios of client protein to CLU in SEC purified HMW 
CLU-CS, HMW CLU-FGN and HMW CLU-GST complexes. SEC purified HMW CLU-client 
protein complexes were separated by reducing SDS-PAGE, stained with Coomasie blue, and analyzed 
using densitometry. The CLU:client protein ratios were calculated as described in the 




 Table 2. CDSSTR predictions of secondary structural content, based on far-UV CD data, for  
(i) unheated or preheated client proteins and CLU, (ii) mixtures of client protein and CLU (unheated or 
separately preheated), and (iii) SEC purified HMW CLU-client protein complexes. Protein samples were 






Fig. 1. CLU inhibits the heat-induced aggregation of CS, FGN and GST. (A) 6.0 μM CS was 
incubated at 41ºC in the presence of  6.6 μM CLU ( ) or 6.5 μM BSA (x). 6.0 μM CS ( ) was also 
incubated alone under the same conditions. (B) 6 μM FGN was incubated at 45ºC in the presence of 
6.5 μM CLU ( ) or 6.5 μM BSA (x). 6 μM FGN ( ) was also incubated alone under the same 
conditions. (C) 20 μM GST was incubated at 60ºC in the presence of 3.2 μM CLU (  ) or 3.2 μM 
BSA (x). 20 μM GST  ( ), 3.2 μM CLU (    ) and 3.2 μM BSA ( ) were also incubated alone under 
the same conditions. The turbidity associated with protein precipitation (A360) was monitored. Data 




Fig. 2. CLU forms HMW complexes with client proteins undergoing stress in vitro. Absorbance 
traces (A280 nm) for SEC. (A) Samples analyzed were unheated and preheated CS and CLU, an 
unheated mixture of CS and CLU, a mixture of preheated CS (*CS) and preheated CLU (*CLU), and 
a heated mixture of CS and CLU (CS + CLU). (B) Samples analyzed were unheated and preheated 
FGN and CLU, an unheated mixture of FGN and CLU, a mixture of preheated FGN (*FGN) and 
preheated CLU (*CLU), and a heated mixture of FGN and CLU (FGN + CLU). (C) Samples analyzed 
were unheated and preheated GST and CLU, an unheated mixture of GST and CLU, a mixture of 
preheated GST (*GST) and preheated CLU (*CLU), and a heated mixture of GST and CLU (GST + 
CLU). The positions of molecular mass standards (kDa) are shown and the exclusion volume (Vo) 
corresponds to molecules  4x 107 Da. The concentration of proteins and the heating conditions used 
were in all cases the same as in the precipitation assays (see EXPERIMENTAL PROCEDURES). The 









Fig. 3. Histograms showing the results of sandwich ELISA demonstrating HMW CLU-client 
protein complexes formed in vitro. Samples analyzed were (A) SEC exclusion limit fraction from a 
heated mixture of CS and CLU (HMW CLU-CS), preheated CS (*CS), preheated CLU (*CLU), and a 
mixture of *CS and *CLU; (B) SEC exclusion limit fraction from a heated mixture of FGN and CLU 
(HMW CLU-FGN), preheated FGN (*FGN), preheated CLU (*CLU), and a mixture of *FGN and 
*CLU; (C) SEC exclusion limit fraction from a heated mixture of GST and CLU (HMW CLU-GST), 
preheated GST (*GST), preheated CLU (*CLU), and a mixture of *GST and *CLU. The conditions 
used to generate the complexes and the preheated proteins, and to perform SEC, were as described in 
EXPERIMENTAL PROCEDURES. Values shown represent the mean of 3 replicates ± standard 
error. + Denotes significantly greater A490 nm compared to all preheated controls (Tukey HSD,  
p  0.01). 
 
 
Fig. 4. Dynamic light scattering estimates of the mean diameters of HMW CLU-client protein 
complexes and other proteins. Samples analyzed were SEC purified HMW complexes of CLU-CS, 
CLU-FGN and CLU-GST, unheated CS, FGN, GST and CLU, preheated CS, FGN, GST and CLU 
(*CS, *FGN, *GST and *CLU, respectively), and mixtures of the preheated client proteins and *CLU. 
The conditions used to generate the complexes and the preheated proteins were as described in 
EXPERIMENTAL PROCEDURES. There was no significant difference in the mean diameters of 
*CLU preheated at 41ºC, 45ºC or 60ºC (only data for *CLU preheated at 60ºC is shown). Histograms 
represent mean diameter ± range of 9 normally distributed curves. 
 
 
Fig. 5. Plots showing time-dependent changes in bisANS fluorescence during heating of CS, 
FGN, GST ± CLU, and CLU alone, in arbitrary fluorescence units (AFU). Samples analyzed were  
(A) CS or CLU alone or CS co-incubated with CLU, (B) FGN or CLU alone or FGN co-incubated 
with CLU, (C) GST or CLU alone or GST co-incubated with CLU. Data points shown represent the 
mean fluorescence of 3 replicates ± standard error. For each plot the 0 h time value has been 
normalized to a value of 10,000 AFU. The conditions used to generate the complexes and the 
preheated proteins were as described in EXPERIMENTAL PROCEDURES. + Denotes increased 
bisANS fluorescence compared to the respective 0 h time value (Tukey HSD, p  0.01).  
 
 
Fig. 6. Far-UV CD spectra. Samples analyzed were (A) CLU and *CLU preheated as indicated, 
unheated and preheated (B) CS, (C) FGN, and (D) GST; (E) SEC purified HMW CLU-CS and mixtures of 
unheated or preheated CS and CLU, (F) SEC purified HMW CLU-FGN and mixtures of unheated or 
preheated FGN and CLU, and (G) SEC purified HMW CLU-GST and mixtures of unheated or preheated 
GST and CLU. The conditions used to generate the complexes and the preheated proteins were as 



























(±, n = 3) 
CLU-CS 9 h, 41°C 1 : 1.81 0.027 1 : 1.17 0.01 
CLU-FGN 12 h, 45°C 1 : 1.88 0.146 1 : 0.34 0.03 
































Sample Helix Sheet Turns Unordered 
CS 69.45 ± 1.39 7.25 ± 1.36 7.70 ± 1.01 15.93 ± 1.16 
*CS 63.95 ± 0.98 11.43 ± 1.10 11.62 ± 0.84 12.92 ± 1.05 
FGN 11.34 ± 0.32 41.36 ± 0.77 20.21 ± 0.69 26.72 ± 1.06 
*FGN 7.09 ± 0.15 32.90 ± 0.12 25.25 ± 0.25 33.58 ± 0.31 
GST 13.88 ± 0.24 33.88 ± 0.52 21.81 ± 0.54 29.96 ± 0.66 
*GST 7.36 ± 0.22 34.32 ± 0.39 24.58 ± 0.50 32.72 ± 0.56 
CLU 34.19 ± 0.10 18.70 ± 0.17 19.89 ± 0.19 26.69 ± 0.25 
*CLU 41°C 39.26 ± 0.23 17.18 ± 0.39 16.81 ± 0.34 26.57 ± 0.52 
*CLU 45°C 15.75 ± 0.22 30.55 ± 0.47 23.83 ± 0.49 29.39 ± 0.61 
*CLU 60°C 14.69 ± 0.21 31.52 ± 0.43 23.00 ± 0.45 30.38 ± 0.63 
HMW CLU-CS 30.59 ± 0.21 21.26 ± 0.37 18.84 ± 0.28 29.33 ± 0.44 
CLU:CS  63.59 ± 0.67 10.15 ± 0.80 10.45 ± 0.78 15.35 ± 1.08 
*CLU:*CS  46.98 ± 0.41 15.69 ± 0.64 15.27 ± 0.51 22.45 ± 0.79 
HMW CLU-FGN 26.25 ± 0.10 22.67 ± 0.18 21.21 ± 0.19 28.82 ± 0.24 
CLU:FGN  26.99 ± 0.09 22.52 ± 0.19 21.15 ± 0.18 28.57 ± 0.27 
*CLU:*FGN  9.38 ± 0.17 32.49 ± 0.22 23.85 ± 0.28 33.64 ± 0.27 
HMW CLU-GST 11.55 ± 0.24 36.83 ± 0.39 21.29 ± 0.38 29.32 ± 0.47 
CLU:GST  33.80 ± 0.18 21.66 ± 0.35 18.54 ± 0.40 25.75 ± 0.54 
*CLU:*GST  11.78 ± 0.25 29.48 ± 0.38 25.93 ± 0.49 32.70 ± 0.46 
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